MCID: FNC007
MIFTS: 42

Functioning Pituitary Adenoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Functioning Pituitary Adenoma

MalaCards integrated aliases for Functioning Pituitary Adenoma:

Name: Functioning Pituitary Adenoma 12 58 15
Secretory Adenoma of the Pituitary Gland 12
Endocrine Active Pituitary Adenoma 58
Pituitary Adenoma, Functioning 70
Secreting Pituitary Adenoma 58

Classifications:

Orphanet: 58  
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:5395
NCIt 50 C8388
UMLS via Orphanet 71 C0854486
Orphanet 58 ORPHA314753
UMLS 70 C0854486

Summaries for Functioning Pituitary Adenoma

MalaCards based summary : Functioning Pituitary Adenoma, also known as secretory adenoma of the pituitary gland, is related to functionless pituitary adenoma and non-functioning pituitary adenoma. An important gene associated with Functioning Pituitary Adenoma is SST (Somatostatin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Aldosterone synthesis and secretion. The drugs Pasireotide and Metformin have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and thyroid, and related phenotypes are cardiovascular system and growth/size/body region

Related Diseases for Functioning Pituitary Adenoma

Diseases related to Functioning Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 269)
# Related Disease Score Top Affiliating Genes
1 functionless pituitary adenoma 32.7 SST POMC IGF1
2 non-functioning pituitary adenoma 32.6 SST S100B GHR GH1 FAM90A1 CDK6
3 tsh producing pituitary tumor 32.5 SSTR5 SST PRL POMC GH1
4 growth hormone secreting pituitary adenoma 32.2 SSTR5 SSTR2 SST PRL POMC MEN1
5 goiter 30.9 TRH SST PRL IGF1
6 insulin-like growth factor i 30.8 SST PRL IGF1 GHR GH1
7 diabetes insipidus 30.8 PRL POMC GH1
8 hypopituitarism 30.6 TRH TBX19 PRL POMC IGF1 GHR
9 lymphocytic hypophysitis 30.6 TBX19 POMC GH1
10 fibrous dysplasia 30.6 SST PRL IGF1 GH1
11 empty sella syndrome 30.6 TRH PRL POMC IGF1 GH1
12 multiple endocrine neoplasia 30.6 SST POMC MEN1 AIP
13 acth-secreting pituitary adenoma 30.6 USP8 TBX19 SSTR5 SSTR2 SST PRL
14 adenoma 30.5 USP8 TRH SSTR5 SSTR2 SST PRL
15 hypothyroidism, congenital, nongoitrous, 4 30.5 PRL POMC GH1
16 gigantism 30.5 PRL GH1 AIP
17 carcinoid syndrome 30.4 SST MEN1 IGF1
18 neuroendocrine carcinoma 30.4 SST S100B MEN1
19 pituitary tumors 30.4 SSTR5 SST PRL POMC MEN1 IGF1
20 pituitary apoplexy 30.4 SST PRL POMC MEN1 IGF1 GH1
21 chromophobe adenoma 30.3 TRH PRL POMC GH1
22 galactorrhea 30.3 PRL IGF1 DRD2
23 mccune-albright syndrome 30.3 SST PRL MEN1 IGF1 GHR GH1
24 paraganglioma 30.3 SST S100B MEN1
25 gangliocytoma 30.3 PRL POMC
26 craniopharyngioma 30.2 TRH PRL IGF1 GH1
27 glucose intolerance 30.2 SST PRL POMC IGF1 GH1
28 hypoglycemia 30.2 SST PRL POMC IGF1 GH1
29 multiple endocrine neoplasia, type i 30.2 SST PRL POMC MEN1 AIP
30 amenorrhea 30.2 TRH PRL POMC IGF1
31 pituitary adenoma 30.2 USP8 TRH SSTR5 SSTR2 SST PRL
32 hyperprolactinemia 30.1 TRH SST PRL POMC IGF1 GH1
33 hypothyroidism 30.1 TRH SST PRL POMC IGF1 GHR
34 neuroendocrine tumor 30.1 SSTR2 SST POMC MEN1 IGF1
35 meningioma, familial 30.1 SSTR5 SSTR2 SST S100B MEN1
36 pituitary adenoma 1, multiple types 30.0 SST PRL MEN1 IGF1 GH1 AIP
37 hyperthyroidism 30.0 TRH SST PRL POMC IGF1 GH1
38 pituitary hormone deficiency, combined, 2 30.0 TRH PRL POMC IGF1 GHR GH1
39 conn's syndrome 29.8 TRH SST PRL POMC MEN1 IGF1
40 hormone producing pituitary cancer 29.8 SSTR5 SSTR2 SST PRL POMC MEN1
41 carney complex variant 29.8 USP8 SST PRL POMC MEN1 IGF1
42 acromegaly 29.8 TRH SSTR5 SSTR2 SST PRL POMC
43 type 2 diabetes mellitus 29.5 SST PRL POMC IGF1 GHR GH1
44 pituitary adenoma, prolactin-secreting 29.2 TRH SSTR5 SSTR2 SST PRL POMC
45 pituitary gland disease 28.1 USP8 TRH TBX19 SSTR5 SSTR2 SST
46 pituitary adenoma 2, growth hormone-secreting 11.7
47 mixed functioning pituitary adenoma 11.3
48 graves disease 1 10.6
49 bronchial adenomas/carcinoids childhood 10.5 SST POMC
50 fibrous dysplasia/mccune-albright syndrome 10.4 PRL GH1

Graphical network of the top 20 diseases related to Functioning Pituitary Adenoma:



Diseases related to Functioning Pituitary Adenoma

Symptoms & Phenotypes for Functioning Pituitary Adenoma

MGI Mouse Phenotypes related to Functioning Pituitary Adenoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.14 AIP CDK6 DRD2 GHR IGF1 MEN1
2 growth/size/body region MP:0005378 10.13 AIP CDK6 DRD2 GHR IGF1 MEN1
3 homeostasis/metabolism MP:0005376 10.13 AIP DRD2 GHR IGF1 MEN1 POMC
4 endocrine/exocrine gland MP:0005379 10.11 AIP CDK6 DRD2 GHR IGF1 MEN1
5 liver/biliary system MP:0005370 9.76 AIP CDK6 DRD2 GHR MEN1 POMC
6 neoplasm MP:0002006 9.56 AIP CDK6 DRD2 IGF1 MEN1 POMC
7 nervous system MP:0003631 9.4 CDK6 DRD2 GHR IGF1 MEN1 POMC

Drugs & Therapeutics for Functioning Pituitary Adenoma

Drugs for Functioning Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pasireotide Approved Phase 4 396091-73-9 9941444
2
Metformin Approved Phase 4 657-24-9 4091 14219
3
Liraglutide Approved Phase 4 204656-20-2 44147092
4
Lactitol Approved, Investigational Phase 4 585-86-4 157355
5
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
6 Hormone Antagonists Phase 4
7 Hormones Phase 4
8 insulin Phase 4
9 Insulin, Globin Zinc Phase 4
10 Hypoglycemic Agents Phase 4
11
protease inhibitors Phase 4
12 HIV Protease Inhibitors Phase 4
13 Sitagliptin Phosphate Phase 4
14 Dipeptidyl-Peptidase IV Inhibitors Phase 4
15 Incretins Phase 4
16 Orange Approved Phase 3
17
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
18
Cabergoline Approved Phase 3 81409-90-7 54746
19
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
20
lanreotide Approved Phase 3 108736-35-2
21 glucocorticoids Phase 2, Phase 3
22 Neurotransmitter Agents Phase 3
23 Dopamine Agents Phase 3
24 Dopamine agonists Phase 3
25 Antiparkinson Agents Phase 3
26 Pharmaceutical Solutions Phase 3
27 Angiopeptin Phase 3
28
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
29
Bexarotene Approved, Investigational Phase 1, Phase 2 153559-49-0 82146
30
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
31
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
32
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
33
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
34
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
35
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
36
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
37
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
38
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
39
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
40
Maleic acid Experimental Phase 2 110-16-7 444266
41 Gastrointestinal Agents Phase 2
42 Neuroprotective Agents Phase 2
43 Methylprednisolone Acetate Phase 2
44 Protective Agents Phase 2
45 Antiemetics Phase 2
46 Antineoplastic Agents, Hormonal Phase 2
47 Anti-Inflammatory Agents Phase 2
48 Histone Deacetylase Inhibitors Phase 2
49 Protein Kinase Inhibitors Phase 2
50 Hydrocortisone hemisuccinate Phase 2

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
2 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
3 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
4 A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
5 A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
6 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape). Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
7 Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study Completed NCT01319994 Phase 2, Phase 3 Metformin;Placebo
8 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
9 Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Completed NCT02180217 Phase 3 osilodrostat;LCI699 matching placebo
10 Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
11 A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease Completed NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
12 Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
13 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas (NFPAs) - a Randomized Controlled Trial Recruiting NCT02288962 Phase 3 cabergoline
14 An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome Active, not recruiting NCT03621280 Phase 3 Levoketoconazole
15 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma From an Endocrinological Point of View (MERGE Study): a Randomized, Phase 3 Trial Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
16 An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
17 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
18 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
19 An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma Completed NCT01283542 Phase 2 Pasireotide LAR
20 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
21 A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
22 A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 in Patients With Cushing's Disease Completed NCT01331239 Phase 2 LCI699
23 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI) Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
24 A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Recruiting NCT03774446 Phase 2 Seliciclib
25 A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease Recruiting NCT03708900 Phase 2 LCI699
26 The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease Recruiting NCT04339751 Phase 2 Vorinostat
27 A One Year, Randomized, Double-Blind, Placebo-Controlled Study of TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas Not yet recruiting NCT04335357 Phase 2 TBR-760;Placebo
28 An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease Terminated NCT00612066 Phase 2 rosiglitazone maleate
29 Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine Terminated NCT02160730 Phase 2 R-roscovitine
30 A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease Terminated NCT01915303 Phase 2 Pasireotide with or without cabergoline
31 Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma Withdrawn NCT01203618 Phase 2 Farletuzumab
32 Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Unknown status NCT01775332
33 Cognitive Sequels of Cushing Syndrome Unknown status NCT02603653
34 A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas Unknown status NCT03309319 Rosiglitazone
35 Etat de santé Des Patients Suivis Pour Une Maladie de Cushing Dans la région Grand-Ouest de 1990 à 2015 Unknown status NCT03297892
36 Characteristics of Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects Completed NCT02574793
37 Cognition, Steroids, and Imaging in Cushings Disease Completed NCT00081341
38 The Factors Associated With the Recurrence in Patients With Cushing Disease Completed NCT02233335
39 Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study Completed NCT01504399
40 National Swedish Study in Cushing´s Disease Incidence and Outcomes Completed NCT02350153
41 Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease Completed NCT03346954
42 Evolution of the Metabolic, Cardiovascular, Bone Complications and of the Quality of Life in Cushing's Disease Completed NCT02568982
43 Predictive Factors of Recurrence of Non Functioning Pituitary Adenomas : a Retrospective Study of 220 Patients in the Reims University Hospital, France Completed NCT02803697
44 Treatment Outcomes for Patients With Cushing's Syndrome: a Prospective Data Collection Study Recruiting NCT03364803
45 Modulating the Glucose-dependent Insulinotropic Polypeptide (GIP) System in Patients With Acromegaly Due to a Pituitary Tumor Recruiting NCT03807076
46 Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study) Recruiting NCT02310269 SOM230
47 Long-Term Follow UP of Survivors of Pediatric Cushing Disease Recruiting NCT03831958
48 A Clinical and Genetic Investigation of Pituitary and HYPOTHALAMIC Tumors and Related Disorders Recruiting NCT00001595
49 Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms: Phase III Diagnostic Evaluation Study Recruiting NCT03974789
50 Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders Recruiting NCT04374721

Search NIH Clinical Center for Functioning Pituitary Adenoma

Genetic Tests for Functioning Pituitary Adenoma

Anatomical Context for Functioning Pituitary Adenoma

MalaCards organs/tissues related to Functioning Pituitary Adenoma:

40
Pituitary, Bone, Thyroid, Brain, Ovary, Prostate, Hypothalamus

Publications for Functioning Pituitary Adenoma

Articles related to Functioning Pituitary Adenoma:

(show top 50) (show all 238)
# Title Authors PMID Year
1
Chiasmapexy for secondary empty sella syndrome: diagnostic and therapeutic considerations. 61
33136230 2021
2
Identifying critical protein-coding genes and long non-coding RNAs in non-functioning pituitary adenoma recurrence. 61
33664827 2021
3
Association of PTP4A3 expression and tumour size in functioning pituitary adenoma: a descriptive study. 61
32616539 2021
4
Giant Non-Functioning Pituitary Adenoma: Clinical Characteristics and Therapeutic Outcomes. 61
31896156 2021
5
Outcome Squares integrating efficacy and safety, as applied to functioning pituitary adenoma surgery. 61
33693739 2021
6
Pituitary disease and pregnancy. 61
33358152 2021
7
Incidence, mortality, and cardiovascular diseases in pituitary adenoma in Korea: a nationwide population-based study. 61
32949324 2021
8
Nomogram predictive model of post-operative recurrence in non-functioning pituitary adenoma. 61
33708562 2021
9
Health-related quality of life in patients with non-functioning pituitary adenoma: a special focus on hydrocortisone replacement dose. 61
32737686 2020
10
Chromosomal and oxidative DNA damage in non-functioning pituitary adenomas. 61
33295635 2020
11
ESE audit on management of Adult Growth Hormone Deficiency in clinical practice. 61
33320830 2020
12
Cephalocaudal tumor diameter is a predictor of diabetes insipidus after endoscopic transsphenoidal surgery for non-functioning pituitary adenoma. 61
33191457 2020
13
Characteristics and clinical outcomes in pituitary incidentalomas and non-incidental pituitary tumors treated with endoscopic transsphenoidal surgery. 61
33126308 2020
14
Identification of a multidimensional transcriptome signature predicting tumor regrowth of clinically non‑functioning pituitary adenoma. 61
32582995 2020
15
Identification of a TMEM127 variant in a patient with paraganglioma and acromegaly. 61
33416299 2020
16
Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness. 61
32656696 2020
17
MRI radiomics for the prediction of recurrence in patients with clinically non-functioning pituitary macroadenomas. 61
32860977 2020
18
The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a 68Ga -DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of lan reotide on t umour size. 61
32792446 2020
19
Comparative analysis of rhinologic outcomes in Cushing disease and non-functioning pituitary adenoma in patients submitted to endoscopic endonasal transsphenoidal surgery. 61
32346754 2020
20
Quality of care evaluation in non-functioning pituitary adenoma with chiasm compression: visual outcomes and timing of intervention clinical recommendations based on a systematic literature review and cohort study. 61
32419072 2020
21
Correction to: Quality of care evaluation in non-functioning pituitary adenoma with chiasm compression: visual outcomes and timing of intervention clinical recommendations based on a systematic literature review and cohort study. 61
32567033 2020
22
Full Remission of Long-Term Premenstrual Dysphoric Disorder-Like Symptoms Following Resection of a Pituitary Adenoma: Case Report. 61
32769963 2020
23
The quality of life after transnasal microsurgical and endoscopic resection of nonfunctioning pituitary adenoma. 61
32745380 2020
24
Current Status of Diagnosis and Management for Functioning Pituitary Tumors: Part I. 61
32611887 2020
25
Non-functioning pituitary adenomas and pregnancy: one-center experience and review of the literature. 61
32267360 2020
26
Cut-off values for sufficient cortisol response to low dose Short Synacthen Test after surgery for non-functioning pituitary adenoma. 61
31907611 2020
27
An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy. 61
31741022 2020
28
Integrated analysis of DNA methylation and mRNA expression profiles to identify key genes involved in the regrowth of clinically non-functioning pituitary adenoma. 61
32015217 2020
29
Preoperative growth hormone (GH) peak values during a GH releasing peptide-2 test reflect the severity of hypopituitarism and the postoperative recovery of GH secretion in patients with non-functioning pituitary adenomas. 61
31776295 2020
30
Giant Non-Functioning Pituitary Adenoma: Clinical Characteristics and Therapeutic Outcomes. 61
31931533 2020
31
Dome-Shaped Pituitary Enlargement in Primary Hypothyroidism: Avoiding Neurosurgical Interventions. 61
33442197 2020
32
Pseudoacromegaly Associated with Non-Functioning Pituitary Adenoma. 61
33313006 2020
33
Identification of key genes in invasive clinically non-functioning pituitary adenoma by integrating analysis of DNA methylation and mRNA expression profiles. 61
31796052 2019
34
T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma. 61
31655798 2019
35
NON-FUNCTIONAL PITUITARY TUMORS: A MISLEADING PRESENTATION OF AN INTRASELLAR PLASMACYTOMA. 61
32377251 2019
36
Functioning Pituitary Adenoma with Xanthogranulomatous Features: Review of Literature and Case Report. 61
31534885 2019
37
Identification of CDK6 and RHOU in Serum Exosome as Biomarkers for the Invasiveness of Non-functioning Pituitary Adenoma. 61
31601299 2019
38
Cavernous sinus haemangioma with intrasellar extension mimicking non-functioning pituitary adenoma - A case report and review of literature. 61
31406488 2019
39
Significance of Elevated HMGB1 Expression in Pituitary Apoplexy. 61
31366550 2019
40
The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study. 61
31374549 2019
41
Unexpected concomitant pituitary adenoma and suprasellar meningioma: a case report and review of the literature. 61
31204511 2019
42
Autoimmune thyroid diseases are more common in patients with prolactinomas: a retrospective case-control study in an Italian cohort. 61
30406929 2019
43
Endocrinological Outcome of Endoscopic Transsphenoidal Surgery for Functioning and Non-Functioning Pituitary Adenoma. 61
31303851 2019
44
Predicting the regrowth of clinically non-functioning pituitary adenoma with a statistical model. 61
31109334 2019
45
Pre-operative MRI predictors of hormonal remission status post pituitary adenoma resection. 61
30731423 2019
46
The burden of disease for pituitary patients. 61
31405752 2019
47
Quality of Life but not Cognition is Impacted by Radiotherapy in Patients with Non-Functioning Pituitary Adenoma. 61
30861564 2019
48
Endocrinological Outcomes of Intraoperative MRI-Guided Endoscopic Transsphenoidal Surgery for Non-Functioning Pituitary Adenoma. 61
30649793 2019
49
Incidence rate and risk factors of early repolarization in patients with growth hormone-secreting pituitary adenoma: a cohort study. 61
30643415 2019
50
Intractable Rathke's cleft cyst hidden behind co-existing giant pituitary adenoma - Case report. 61
30610983 2019

Variations for Functioning Pituitary Adenoma

Expression for Functioning Pituitary Adenoma

Search GEO for disease gene expression data for Functioning Pituitary Adenoma.

Pathways for Functioning Pituitary Adenoma

GO Terms for Functioning Pituitary Adenoma

Cellular components related to Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 SST S100B PRL POMC MIR93 IGF1
2 endosome lumen GO:0031904 9.16 PRL GH1
3 growth hormone receptor complex GO:0070195 8.62 GHR GH1

Biological processes related to Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.14 TRH SSTR5 SSTR2 PRL POMC IGF1
2 neuropeptide signaling pathway GO:0007218 9.7 SSTR5 SSTR2 POMC
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 IGF1 GHR GH1
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 IGF1 GHR GH1
5 insulin-like growth factor receptor signaling pathway GO:0048009 9.51 IGF1 GHR
6 positive regulation of JAK-STAT cascade GO:0046427 9.5 PRL GHR GH1
7 growth hormone receptor signaling pathway GO:0060396 9.48 GHR GH1
8 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.46 IGF1 GH1
9 positive regulation of multicellular organism growth GO:0040018 9.43 GHR GH1 DRD2
10 peristalsis GO:0030432 9.4 SSTR2 DRD2
11 somatostatin signaling pathway GO:0038170 9.37 SSTR5 SSTR2
12 regulation of multicellular organism growth GO:0040014 9.33 PRL IGF1 GHR
13 negative regulation of cell proliferation GO:0008285 9.17 SSTR5 SSTR2 SST MIR93 MEN1 DRD2
14 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.13 PRL GHR GH1

Molecular functions related to Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 somatostatin receptor activity GO:0004994 9.16 SSTR5 SSTR2
2 hormone activity GO:0005179 9.1 TRH SST PRL POMC IGF1 GH1
3 prolactin receptor binding GO:0005148 8.96 PRL GH1

Sources for Functioning Pituitary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....